Will Blood Substitutes Deliver?
This article was originally published in Start Up
Executive Summary
Developers of blood substitutes struggle to design clinical trials that show their products can reduce patients’ exposure to donated blood. But manufacturing and scale-up issues present tough challenges, especially for hemoglobin-based products. Newclinical procedures can help blood substitutes perform better, but will require significant physician education. Partnership may prove key in reaching a market analysts estimate at $2-$10 billion.